GS
33
-6
OKE
52
-6
SO
60
-4
AMP
55
-2
SPG
30
2
PVH
40
-2
TRIP
60
2
ROP
54
-2
NWSA
48
-2
CPB
54
-3
UNM
59
-9
GRMN
43
3
CSCO
47
2
PH
55
3
VRSK
22
3
CL
54
-2
UNP
33
8
SNA
42
-8
FLR
56
-13
CCL
26
-3
GS
33
-6
OKE
52
-6
SO
60
-4
AMP
55
-2
SPG
30
2
PVH
40
-2
TRIP
60
2
ROP
54
-2
NWSA
48
-2
CPB
54
-3
UNM
59
-9
GRMN
43
3
CSCO
47
2
PH
55
3
VRSK
22
3
CL
54
-2
UNP
33
8
SNA
42
-8
FLR
56
-13
CCL
26
-3
Financhill
Back

Akero Therapeutics Quote, Financials, Valuation and Earnings

R.I.P. for the American Dream? (Surprising answer inside...)

Go here now for the details.
Sell
40

AKRO
Akero Therapeutics

Last Price:
45.92
Seasonality Move:
9.48%

7 Day Trial

ALL ACCESS PASS

$ 7

Unexpected gains from AI stocks

Click here to see the proof for yourself.

Akero Therapeutics Price Quote

$45.92

Akero Therapeutics Key Stats

Sell
40
Akero Therapeutics (AKRO) is a Sell
Day range:
$45.87 - $48.92
52-week range:
$25.21 - $58.38
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
4.14%
Volume:
881.2K
Avg. volume:
888.8K
1-year change:
75.4%
Market cap:
$2.6B
Revenue:
$0
EPS:
$-2.56

How Much Does Akero Therapeutics Make?

Data Unavailable

Is Akero Therapeutics Growing As A Company?

Data Unavailable

Akero Therapeutics Stock Price Performance

What Is Akero Therapeutics 52-Week High & Low?

Akero Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akero Therapeutics?

Is Akero Therapeutics Cash Flow Positive?

  • What Is AKRO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$97.2M
  • What Is Akero Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $572.6M
  • What Is Akero Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$209.2M

Akero Therapeutics Return On Invested Capital

Data Unavailable

Akero Therapeutics Earnings Date & Stock Price

Akero Therapeutics Competitors

  • Who Are Akero Therapeutics's Competitors?
    Below is a list of companies who compete with Akero Therapeutics or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • 89bio Inc (ETNB)
    • Eli Lilly and Co (LLY)
    • Madrigal Pharmaceuticals Inc (MDGL)
    • Viking Therapeutics Inc (VKTX)

Akero Therapeutics Dividend Yield

Data Unavailable

Akero Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 11.77%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 67.89
Upside from Last Price: 47.84%

Major Shareholders

  • How many AKRO shares are owned by institutional investors?
    80.9M AKRO shares are owned by institutional investors
  • How many AKRO shares are owned by insiders?
    1M AKRO shares are owned by insiders